Articular and Pancreatic Involvement in Pyoderma gangrenosum Associated with Myelodysplastic Syndrome

Ochiai, Toyoko; Hara, Hiroyuki; Shimojima, Hiroyuki; Fujitsuka, Ayako; Morishima, Takafumi; Yamazaki, Tetsuo; Sawada, Umihiko

doi:10.1159/000063137

Cited by 9 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Association with several systemic diseases has been noted, including inflammatory bowel disease, rheumatoid arthritis, autoimmune disorders and hematological malignancies [1, 2, 3]. Immunosuppressive therapies, such as corticosteroids and cyclosporine, are now the most commonly used treatments with variable effectiveness.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Pyoderma gangrenosum with Low-Dose Colchicine

Kontochristopoulos¹,

Stavropoulos

Gregoriou³

et al. 2004

Dermatology

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis of unknown origin. Systemic agents occasionally administered provide either incomplete long-term control of the disease or have been associated with serious adverse side effects after chronic administration. We present two patients with PG successfully treated with low-dose colchicine. Antimitotic, anti-inflammatory and immunomodulating properties of colchicine might account for its beneficial effects in PG patients. Colchicine is effective and well tolerated in low doses by most patients. In addition, it is inexpensive and safer for long-term treatment than corticosteroids and other immunosuppressive agents. Colchicine may be proposed either as a single agent or as a corticosteroid-sparing agent for early treatment of PG.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of Pyoderma gangrenosum with Low-Dose Colchicine

Kontochristopoulos¹,

Stavropoulos

Gregoriou³

et al. 2004

Dermatology

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12][13] This report has described one such rare patient. The skin lesion of PG is sometimes misdiagnosed as infectious dermatitis.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome

Yamauchi

Ishida

Iwashima

et al. 2003

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

“…Other systemic extracutaneous involvements of PG have been reported sporadically and are even more rare (Fig. 3) which include joints [16,43,47], pituitary granuloma [12], aortitis [36], myositis [25,37], and ileal pouchitis [1] (Table 2).…”

Section: Other Extracutaneous Involvementmentioning

confidence: 99%

Extracutaneous involvement of pyoderma gangrenosum

et al. 2019

View full text Add to dashboard Cite

Pyoderma Gangrenosum (PG) is an inflammatory neutrophilic dermatosis (ND) associated with underlying chronic inflammation and/or malignancy. Diagnosis remains to be challenging as a gold standard diagnostic test is lacking. Initial manifestations may include papules, vesicles, or pustules that subsequently develop into ulceration with features of undermining and violaceous borders. Timely recognition of pyoderma gangrenosum is impeded by clinical findings shared with other etiologies, such as granulomatosis with polyangiitis, polyarteritis nodosa, and antiphospholipid syndrome. As with any other ND, extracutaneous involvement may also occur preceding, during, or following the appearance of skin lesions. Sterile neutrophilic infiltrates have been found to affect internal organs supporting the concept of PG being a systemic disease, with lung being the most common extracutaneous manifestation followed by ocular and visceral compromise. Therefore, in this review, we describe the current knowledge of extracutaneous involvement of PG and its respective clinical manifestations to aid dermatologists in diagnosis, management, and determining prognosis.

show abstract

Articular and Pancreatic Involvement in Pyoderma gangrenosum Associated with Myelodysplastic Syndrome

Cited by 9 publications

References 20 publications

Treatment of Pyoderma gangrenosum with Low-Dose Colchicine

Treatment of Pyoderma gangrenosum with Low-Dose Colchicine

Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome

Extracutaneous involvement of pyoderma gangrenosum

Contact Info

Product

Resources

About